Alexander Hray, MD
Family Medicine · Beaufort, SCNPI 1083909121
Payments from drug & device makers
Across 137 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$427
- GSK$237
- Pfizer$207
- Novo Nordisk$188
- Astellas Pharma US Inc$170
- AstraZeneca$123
- plus $926 from 22 others
What the payments were for
- Food & beverage$2,279100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 32 | $427 |
| GSK | 11 | $237 |
| Pfizer | 12 | $207 |
| Novo Nordisk | 14 | $188 |
| Astellas Pharma US Inc | 10 | $170 |
| AstraZeneca | 8 | $123 |
| Boehringer Ingelheim | 7 | $120 |
| Novartis | 6 | $117 |
| Amgen | 8 | $114 |
| Johnson & Johnson | 5 | $67 |
| Abiomed | 2 | $63 |
| Dexcom, Inc. | 2 | $50 |
| Abbott | 2 | $42 |
| Lilly USA, LLC | 3 | $39 |
| Exact Sciences | 2 | $35 |
| Stryker | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Alnylam Pharmaceuticals Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Inari Medical, Inc. | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Merck | 1 | $21 |
| Atricure, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Bayer | 1 | $13 |
How this compares
$2,279 in reported general payments places this provider in the 70th percentile of 2,153 family medicine providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 136 | $156,690 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 72 | $88,310 |
| OzempicSemaglutide | 61 | $85,214 |
| JardianceEmpagliflozin | 68 | $75,517 |
| JanuviaSitagliptin Phosphate | 58 | $58,169 |
| FarxigaDapagliflozin Propanediol | 42 | $47,116 |
| XareltoRivaroxaban | 19 | $29,883 |
| EntrestoSacubitril/Valsartan | 26 | $29,199 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 32 | $26,264 |
| LinzessLinaclotide | 18 | $25,749 |
| RybelsusSemaglutide | 16 | $23,952 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 19 | $22,494 |
| MyrbetriqMirabegron | 19 | $21,020 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $21,016 |
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $20,389 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $207 | $156,690136 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta | $237 | $121,232119 claims |
| Novo NordiskOzempic, Rybelsus | $188 | $109,16777 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $120 | $85,20383 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $123 | $72,46571 claims |
| MerckJanuvia, Steglatro | $21 | $63,49872 claims |
| Johnson & JohnsonXarelto | $67 | $29,88319 claims |
| NovartisEntresto | $117 | $29,19926 claims |
| AbbVieLinzess | $427 | $25,74918 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $15 | $22,49419 claims |
| Astellas Pharma US IncMyrbetriq | $170 | $21,02019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,153 family medicine providers in South Carolina.
Other family medicine in Beaufort
- Cayce TangemanGoose Creek$8.4M
- Jeremy AckermannMoncks Corner$7.6M
- Kelly MoralesNorth Charleston$6.5M
- William ByarsGreer$4.8M
- James FranklinGreenville$3.5M
- Stephen GrubbLittle River$3.4M
- Jeffrey HarrisGreenville$3.4M
- Shannon ConradN Charleston$3.3M
- Tom ChristensenLittle River$3.1M
- Edward NewtonCharleston$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.